Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR)

Synaptogenix (NASDAQ:SNPX) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Volatility & Risk

Synaptogenix has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Valuation & Earnings

This table compares Synaptogenix and Clever Leaves”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A
Clever Leaves	$17.42 million	0.00	-$17.90 million	($11.31)	N/A

Synaptogenix has higher earnings, but lower revenue than Clever Leaves.

Profitability

This table compares Synaptogenix and Clever Leaves’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-7.45%	-5.65%
Clever Leaves	N/A	N/A	N/A

Insider and Institutional Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 4.3% of Synaptogenix shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Synaptogenix and Clever Leaves, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	0	0	1	0	3.00
Clever Leaves	0	0	0	0	N/A

Synaptogenix currently has a consensus price target of $14.00, suggesting a potential upside of 396.45%.

Summary

Clever Leaves beats Synaptogenix on 5 of the 8 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.